Spiriva Respimat solution 2.5mcg/dose 4ml

Spiriva Respimat instruction for use

You can buy Spiriva Respimat on this page

pharmachologic effect

Spiriva has anticholinergic, bronchodilating action.

Spiriva Respimat, indications for use

As maintenance therapy in patients with COPD, including chronic bronchitis and emphysema (with persistent dyspnea and to prevent exacerbations).

Contraindications

Hypersensitivity (including to atropine or its derivatives, for example, ipratropium or oxotropy), I trimester of pregnancy, age to 18 years.

Dosing and Administration

Recommended dose of Spiriva Respimat - 2 inhalations (2 breaths) of aerosol by inhalation device Respimat.
Inhalation should be carried out once a day at the same time.
In patients of advanced age, Spiriva Respimat can be used according to the recommended dose.
In patients with renal insufficiency, Spiriva Respimat may be administered according to the recommended dose. The use of Spiriva Respimat, as well as other drugs that are mainly excreted by the kidneys, should be performed under medical supervision in patients with moderate and severe renal insufficiency. In patients with hepatic insufficiency, the drug can be administered according to the recommended dose.

Instructions for use

Follow these instructions carefully.
Installing the cartridge and preparing it for use
Before the first use it is necessary:
1. With the green cap closed, press the fuse and push out the transparent base.
2. Remove the cartridge from the box. Insert the narrow end of the cartridge into the inhaler until it clicks, becoming in place. The cartridge must be pressed gently against the hard surface to ensure that it is fully installed in place. Do not remove the cartridge after it has been installed in the inhaler.
3. Insert the transparent base into place. Do not remove the transparent substrate again.
In order to prepare the Spiriva Respimat inhaler for the first use:
4. Inhaler Spiriva Respimat is held in the right hand with a closed green cap. Rotate the transparent base in the direction of the red arrows on the label until it clicks (half turn).
5. Open the green cap until it completely opens.
6. Direct the inhaler Spiriva Respimat downwards. Press the button to release the dose. Close the green cap.
Repeat steps 4, 5 and 6 until an aerosol appears.
Then repeat steps 3, 4, 5 and 6 3 times to make sure that the inhaler is ready for use.
Now the Spiriva Respimat inhaler is ready for use.
These steps do not affect the number of doses available. After preparation, the Spiriva Respimat inhaler is designed for 30 doses (60 breaths).

Application in pregnancy and lactation

Clinical data on the safety and efficacy of the drug Spiriva Respimat during pregnancy are not available.
In preclinical studies, no indication of direct or indirect adverse effects on pregnancy, embryo / fetal development, delivery process or postnatal development has been obtained.
There are no clinical data on the safety and efficacy of tiotropium bromide during breastfeeding.
The drug Spiriva Respimat should not be used in pregnant or breast-feeding women, unless the potential benefit to the mother exceeds the potential risk to the fetus and the baby. For the period of application of the drug, it is necessary to stop breastfeeding the baby.

Side effects of Spiriva Respimat

Many of these undesirable effects can be attributed to the anticholinergic properties of Spiriva Respimat.
Criteria for assessing the incidence of adverse drug reactions:> 10% - very often; 1-10% - often; 0.1-1% - infrequently; 0,01-0,1% - rarely; From the side of metabolism, metabolism: the frequency is unknown - dehydration.
From the nervous system: infrequently - dizziness; frequency is unknown - insomnia.
From the side of the organ of vision: infrequently - blurred vision; rarely - glaucoma, increased intraocular pressure.
From the cardiovascular system: infrequently - atrial fibrillation, palpitation, supraventricular tachycardia, tachycardia.
On the part of the respiratory system: infrequently - cough, nosebleeds, pharyngitis, dysphonia; rarely - bronchospasm, laryngitis; the frequency is unknown - sinusitis.
From the gastrointestinal tract: often - dry mouth, usually mild; infrequently - constipation, oropharyngeal candidiasis, dysphagia; rarely - GERD, gingivitis, glossitis, stomatitis; frequency unknown - intestinal obstruction including paralytic ileus.
From the skin and the immune system: infrequent - rashes, itching; rarely - angioedema, hives, skin infections and skin ulcers, dry skin; frequency unknown - hypersensitivity (including allergic reactions of immediate type).
From the side of the locomotor system and connective tissue: the frequency is unknown - swelling of the joints.
From the urinary system: infrequently - urinary retention (usually in men predisposed to this), urination disorders; rarely - urinary tract infection.

special instructions

Spiriva Respimat is a bronchodilator, which is prescribed once a day for maintenance therapy. The drug is not intended for the initial treatment of an acute attack of bronchospasm, that is, for emergency care.
Hypersensitivity reactions may occur after application of r-ra for inhalations of Spiriva Respimat.
Spiriva Respimat is used with caution in patients with closed-angle glaucoma, prostatic hyperplasia or obstruction of the neck of the bladder.
The use of inhaled medications can cause bronchospasm caused by their carrying out.
There is an increased risk of fatal cases in patients with a heart rhythm disorder. The connection of cardiac arrhythmia with a fatal outcome is questionable, in addition, a causal relationship with tiotropium Respimat is not established. The use of Spiriva Respimat, mainly excreted by the kidneys, should be performed under medical supervision in patients with moderate and severe renal insufficiency (creatinine clearance Patients should be instructed on the correct administration of Spiriva Respimat.) It is inadmissible to get either r-ra or aerosol in the eye. pain or discomfort in the eyes, blurred vision, the appearance of a halo or color spots in front of the eyes in combination with reddened eyes in the form of congestion
Cartridges Spiriva should be used only with the inhaler Respimat.
During pregnancy and breastfeeding. The drug should not be used during pregnancy and lactation without evaluating the relationship between expected benefit and possible risk to the fetus or child.
Children. The drug Spiriva Respimat is not recommended for use in children due to lack of data regarding efficacy and safety.
The ability to influence the reaction rate when driving vehicles and working with other mechanisms. For the period of treatment should refrain from driving and working with other mechanisms, taking into account the possibility of dizziness or blurry vision.

Drug Interactions

Despite the fact that special studies of interaction with other drugs were not conducted, tiotropium bromide was used concomitantly with other drugs (sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids, which are used in the treatment of COPD) without adverse reactions. The study of the permanent simultaneous use of tiotropium bromide with other anticholinergic drugs was not conducted. Moreover, the constant simultaneous use of anticholinergic drugs with Spiriva Respimat is not recommended.

Overdose

The use of the drug Spiriva Respimat in high doses can cause anticholinergic signs and symptoms: dryness of the mucous membranes of the mouth / throat and nasal cavity with a dose-dependent frequency, a decrease in salivary secretion.
Acute intoxication due to accidental oral administration of r-tiotropium for inhalations from the cartridge is unlikely due to low bioavailability when administered orally.

Storage conditions

In the dark place at a temperature of no higher than 25 ° C

Terms of sell

You can buy Spiriva Respimat without a prescription.